Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Update

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the target of a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 38,900 shares, a decline of 68.0% from the February 13th total of 121,400 shares. Approximately 0.2% of the company’s stock are short sold. Based on an average daily trading volume, of 153,700 shares, the short-interest ratio is presently 0.3 days.

Bolt Biotherapeutics Stock Up 3.9 %

Shares of NASDAQ:BOLT opened at $0.42 on Friday. The company has a current ratio of 3.16, a quick ratio of 3.16 and a debt-to-equity ratio of 0.21. The company has a fifty day simple moving average of $0.49 and a 200 day simple moving average of $0.57. The firm has a market cap of $16.02 million, a PE ratio of -0.24 and a beta of 0.94. Bolt Biotherapeutics has a 12-month low of $0.40 and a 12-month high of $1.56.

Institutional Trading of Bolt Biotherapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. FMR LLC increased its stake in shares of Bolt Biotherapeutics by 33.2% in the third quarter. FMR LLC now owns 115,386 shares of the company’s stock worth $75,000 after buying an additional 28,773 shares during the last quarter. Millennium Management LLC bought a new stake in shares of Bolt Biotherapeutics in the fourth quarter worth $25,000. Squarepoint Ops LLC bought a new stake in shares of Bolt Biotherapeutics in the fourth quarter worth $26,000. Velan Capital Investment Management LP bought a new stake in shares of Bolt Biotherapeutics in the fourth quarter worth $27,000. Finally, Citadel Advisors LLC bought a new stake in shares of Bolt Biotherapeutics in the fourth quarter worth $42,000. Institutional investors own 86.70% of the company’s stock.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.